A variety of approaches to measure the efficacy of PARP inhibitors
A variety of approaches to measure the efficacy of PARP inhibitors
Development and clinical indications of PARP inhibitors
AKT inhibitors in research and application
Increasing diversity through the NCI SBIR development centre
Clinical development and economic prospects of CAR T cell immunotherapies
Response and safety profile of neoadjuvant nivolumab for resectable lung cancer
Doubled survival in metastatic lung cancer with combination therapy
Combined immuno-chemotherapy improves survival and responses in metastatic lung cancer
Results from CheckMate-227 : Immune combination reaches PFS endpoint
Editor’s Choice for March 2018
Editor's Choice for February 2018
PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trial